Inactive Instrument

Alopexx, Inc.

Equities

ALPX

US02052J1016

Biotechnology & Medical Research

Alopexx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 14, 2024 at 04:10 pm

Alopexx, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 3.78 million compared to USD 2.32 million a year ago. Basic loss per share from continuing operations was USD 0.81 compared to USD 0.5 a year ago.

Latest news about Alopexx, Inc.

Alopexx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Alopexx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	12-27	CI
Alopexx to Present Data on F598, a Novel, Broad-Spectrum Immunotherapeutic at IDWeek 2023	23-10-12	CI
Alopexx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-18	CI
Alopexx, Inc. has filed an IPO in the amount of $18.328125 million.	22-03-04	CI

Chart Alopexx, Inc.

Duration

Period

More charts

Company Profile

Alopexx Inc. is a clinical-stage biotechnology company. The Company is engaged in developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). The Company's immune therapeutics target the conserved microbial surface polysaccharide poly N-acetyl glucosamine (PNAG). The Company's vaccine candidate, Vaccine AV0328, is a synthetic PNAG vaccine. It induces antibodies that are capable of killing a wide range of PNAG-expressing pathogens. AV0328 be developed as a complement to Streptococcus pneumonia vaccines (Prevnar, Pneumovax, and Vaxneuvance). AV0328 could protect against many of approximately 80 serotypes. Its Monoclonal antibody F598 is a human monoclonal antibody. It will not replace antibiotics but will instead complement and augment their efficacy and by doing so reduce the development of antibiotic-resistant organisms.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research